• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Bon Natural Life Limited Announces Receipt of Nasdaq Delisting Notifications

    5/2/25 4:10:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $BON alert in real time by email

    XI'AN, China, May 02, 2025 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, announced today that on April 29, 2025, the Company received a letter (the "Notification Letter") from the Listing Qualifications Staff (the "Staff") of The Nasdaq Stock Market, LLC ("Nasdaq"), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5450(a)(1) (the "Minimum Bid Price Requirement"), as the Company's closing bid price for its Class A ordinary shares, par value US$0.001 per share was below $1.00 per share for the prior thirty (30) consecutive business days, which matter serves as a basis for delisting the Company's securities from Nasdaq. Additionally, the Company's securities had a closing bid of $0.10 or less for the last ten consecutive trading days, and accordingly, is subject to the provisions under Listing Rule 5810(c)(3)(A)(iii). This serves as an additional basis for delisting, and as such, the Company is not eligible for a compliance period. 

    On May 1, 2025, the Company received an additional Notification Letter notifying the Company that the Staff has determined to delist the Company's securities pursuant to their discretionary authority under Listing Rule 5101. The Staff's determination was based on public interest concerns in relation to the Company's March 2025 best efforts offering.

    The Company has filed a notice of appeal and requested a hearing before a Nasdaq Listing Qualifications Panel to review the Staff's determination. The appeal will stay delisting of the Company's securities pending the Panel's decision.

    The Company will evaluate available options to regain compliance with the aforementioned Listing Rules. However, there are no assurances that the Company will be able to regain or maintain compliance or that any such appeal to the Panel will be successful, as applicable.

    About Bon Natural Life Limited

    BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit http://www.bnlus.com.

    Forward-Looking Statements

    Certain statements in this announcement are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Investors can identify these forward-looking statements by words or phrases such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or other similar expressions. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results. These forward-looking statements are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, activities of regulators and future regulations and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Therefore, you should not rely on any of these forward-looking statements. These risks and uncertainties include, among others: the completion of the offering, the satisfaction of customary closing conditions related to the offering, the intended use of proceeds from the offering, BON's limited operating history and historical losses; BON's ability to raise additional funding; competition from third parties that are developing or have products for similar uses; BON's ability to obtain, maintain and protect its intellectual property; and BON's expectations regarding its growth, strategy, progress towards its goals. These forward-looking statements involve known and unknown risks and uncertainties and are based on current expectations and projections about future events and financial trends that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company undertakes no obligation to update forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations, except as may be required by law. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company's registration statement and in its other filings with the U.S. Securities and Exchange Commission.

    Investor Relations Contact:

    Cindy Liu | IR

    Email: [email protected]



    Primary Logo

    Get the next $BON alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BON

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $BON
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BON Announces Breakthrough Development of Apple Bio-Electronic Mask: Clinical Data Exceeds Expectations, Targeting $100B+ Medical Aesthetics Market

    XI'AN, China, Feb. 19, 2026 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("Bon" or the "Company"), a leading provider of bio-ingredient solutions in the natural, health, and personal care industries, today announced the successful development of a premium anti-aging facial mask incorporating apple polyphenols as its core active ingredient and integrated with AI-enabled flexible bio-electronic technology. Leveraging advanced transdermal delivery systems, this product integrates plant-derived active ingredients with intelligent flexible electronics, creating a next-generation skin care solution designed to be non-invasive, painless, and suitable for at-home use. Serving as the core na

    2/19/26 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Partners with Chang'an Pilot to Launch World-Class Joint Laboratory for Natural Ingredient Bio-manufacturing

    XI'AN, China, Feb. 17, 2026 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON"or the "Company"), a leading bio-ingredient provider for the natural health and personal care industries, today announced the establishment of the BON & Pilot Joint Laboratory for Natural Ingredients and Bio-Manufacturing (the "Joint Laboratory"). The Joint Laboratory was inaugurated on December 18, 2025 through a collaboration between the Company's domestic operating subsidiary, Xi'an App-Chem Bio-Tech Co., Ltd., and Shaanxi Chang'an Pilot Life Science Industry Innovation Center Co., Ltd. ("Chang'an Pilot"). The Joint Laboratory will focus on the research and development of bio-manufactured natural activ

    2/17/26 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    BON Unveils Kombucha-Inspired Product, Inks $12 Million Strategic Sales Agreement with Qingshengyuan

    XI'AN, China, Dec. 10, 2025 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced the launch of a new health-focused kombucha-inspired product and a strategic collaboration with Shaanxi Qingshengyuan Health Industry Co., Ltd. ("Qingshengyuan"), a leading distributor of functional health products in China focusing on digestive and metabolic wellness. The two parties entered into a non-exclusive strategic sales agreement. The term of the agreement is 24 months with a total contract value of $12 million. Pursuant to the agreement, Qingshengyuan will sell and di

    12/10/25 4:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    SEC Filings

    View All

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    2/17/26 9:00:13 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    12/10/25 6:15:05 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    SEC Form 6-K filed by Bon Natural Life Limited

    6-K - Bon Natural Life Ltd (0001816815) (Filer)

    11/25/25 9:30:02 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Leadership Updates

    Live Leadership Updates

    View All

    Bon Natural Life Limited Appoints Wallace Lee as New Chief Financial Officer

    XIAN, China, April 25, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, is pleased to announce the appointment of Mr. Wallace Lee as Chief Financial Officer (CFO), effective April 17, 2023. Mr. Lee succeeds Zhenchao Li, who stepped down from the role of CFO after a 4-year career with the Company, effective April 17, 2023. "We welcome Wallace Lee into BON's executive leadership team." Commented Richard Hu, "Wallace brings exceptional financial, strategic, and operational experience both from multiple industry sectors and experience as a public c

    4/25/23 8:30:00 AM ET
    $BON
    $SXTC
    $WSG
    Medicinal Chemicals and Botanical Products
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Services-Misc. Amusement & Recreation

    Bon Natural Life Limited Announces Change to Board Composition

    XIAN, China, June 30, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, today announced the appointment of Jeffrey Guzy, as a new independent Director to its Board of Directors and as Chair of the Audit Committee, both effective June 28, 2022. Effective June 27, 2022, Mr. Christopher Constable resigned as a director of the Company for personal reasons and stepped down as a member and chairman of the audit committee of the Board. The resignation of Mr. Constable did not result from any dispute or disagreement with the Company or the Board on any matter

    6/30/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    $BON
    Financials

    Live finance-specific insights

    View All

    Bon Natural Life Limited Announces FY2022 Earnings Release Date and Webcast

    Earnings to be released before market opens on Friday, February 10, 2023 XIAN, China, Feb. 07, 2023 (GLOBE NEWSWIRE) -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2022 earnings release for the fiscal year ended September 30, 2021 before the market open on Friday, February 10, 2023. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be

    2/7/23 8:30:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces 2022 Half-Year Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, August 1, 2022XIAN, China, July 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its half-year earnings release for the reporting period ended March 31, 2022 before the market open on Monday, August 1, 2022. BON will also host an investor conference call and webcast on the same date, beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, COO Ms. Yingchun Xue and CMO Wenjuan Chen. A replay of the call will also be archived o

    7/28/22 4:30:00 PM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care

    Bon Natural Life Limited Announces FY2021 Earnings Release Date and Webcast

    Earnings to be released before market opens on Monday, January 31, 2022 XI'AN, China, Jan. 28, 2022 /PRNewswire/ -- Bon Natural Life Limited (NASDAQ:BON) ("BON" or the "Company"), one of the leading bio-ingredient solutions providers in the natural, health and personal care industries, will issue its FY2021 earnings release for the fiscal year ended September 30, 2021 before the market open on Monday, January 31, 2022. In observation of Chinese New Year, BON will host an investor conference call and webcast on February 3 beginning at 9:00 a.m. EST. Management on the call will include CEO Mr. Richard (Yongwei) Hu, CFO Mr. Zhenchao Li, CMO Ms. Wenjuan Chen and COO Ms. Yingchun Xue. A replay

    1/28/22 9:00:00 AM ET
    $BON
    Medicinal Chemicals and Botanical Products
    Health Care